PresSura Neuro
LEAD PROGRAMME
Moderate to Severe
Traumatic Brain Injury.
EU-C-001 is a compound targeting the control of elevated intracranial pressure following traumatic brain injury. It is in a Phase 2A double-blind trial across multiple countries, and enrolment is complete. The trial follows a Phase 1 programme and an open-label phase.
About PresSura Neuro.
PresSura Neuro is a biopharmaceutical company, developing EU-C-001 for the treatment of:
Elevated intracranial pressure (ICP) following moderate to severe traumatic brain injury (TBI)
Stroke
The effects from concussions including CTE, TES and PCS
PresSura Neuro is targeting conditions that currently have no regulatory approved medications.
PresSura Neuro is the trading name for Eustralis Pharmaceuticals Ltd, based in Melbourne, Australia. Formed in 2005, PresSura Neuro licensed compounds from Hoffmann-La Roche (Switzerland) to develop solutions for a range of neurological conditions for which there are currently no treatments including TBI, stroke and concussion/PCS.